---
title: "INSMED Chair and CEO William Lewis Sells 13,396 Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275664348.md"
description: "INSMED's Chair and CEO, William Lewis, sold 13,396 shares of common stock on February 9, 2026, under a 10b5-1 trading plan, totaling $1,979,763. The shares were sold at average prices of $147.17, $148.02, and $148.83. Post-sale, Lewis holds 301,185 shares directly and 284,424 shares indirectly through trusts."
datetime: "2026-02-11T21:50:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275664348.md)
  - [en](https://longbridge.com/en/news/275664348.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275664348.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275664348.md) | [繁體中文](https://longbridge.com/zh-HK/news/275664348.md)


# INSMED Chair and CEO William Lewis Sells 13,396 Shares

INSMED's Chair and CEO, William Lewis, sold a total of 13,396 shares of common stock on February 9, 2026, under a 10b5-1 trading plan. The transactions occurred at weighted average prices of $147.17, $148.02, and $148.83, resulting in a total sale amount of $1,979,763. Following these transactions, Lewis directly owns 301,185 shares and indirectly owns 284,424 shares of INSMED common stock through the Katie Procter Dynasty Trust and the William Lewis Family Legacy Trust.

Reporter Name

Lewis William

Relationship

Chair and CEO

Type

Sell

Amount

$1,979,763

SEC Filing

Form 4

SEC Filing: INSMED Inc \[ INSM \] - Form 4 - Feb. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Insmed Incorporated (INSM.US)](https://longbridge.com/en/quote/INSM.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Invesco Dorsey Wright Healthcare MomtETF (PTH.US)](https://longbridge.com/en/quote/PTH.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Mirum Pharmaceuticals Executives Sell Shares](https://longbridge.com/en/news/279503772.md)
- [Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results](https://longbridge.com/en/news/279269040.md)
- [Pfizer announces positive topline phase 2 results for next-generation CDK4 inhibitor, atirmociclib, in second-line metastatic breast cancer](https://longbridge.com/en/news/279429425.md)
- [BUZZ-Structure rises after obesity pill shows up to 16.3% weight loss in study](https://longbridge.com/en/news/279254910.md)
- [Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III](https://longbridge.com/en/news/279532083.md)